Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-158 pembrolizumab biomarker trial in advanced solid tumors
2022-501253-37-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in anal squamous cell carcinoma (SCCA), biliary adenocarcinoma, apudoma (NET) and 8 more, sponsored by Merck & Co. Primary endpoint: Objective response rate. Planned start Feb 2016; status: authorised.
02
Drugs
03
Conditions
anal squamous cell carcinoma (SCCA)biliary adenocarcinomaapudoma (NET)endometrial cancer (EC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on 2022-501253-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501253-37-00.